```
ENTER A FILE NAME OR (IGNORE):medline caplus

COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.30       0.30

FILE 'MEDLINE' ENTERED AT 19:04:17 ON 09 AUG 2000

FILE 'CAPLUS' ENTERED AT 19:04:17 ON 09 AUG 2000
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2000 AMERICAN CHEMICAL SOCIETY (ACS)

=> s thrombocyte

L1         3815 THROMBOCYTE

=> s l1 and wound (w) healing

L2           10 L1 AND WOUND (W) HEALING

=> duplicate remove l2

DUPLICATE PREFERENCE IS 'MEDLINE, CAPLUS'
KEEP DUPLICATES FROM MORE THAN ONE FILE?  Y/(N):n

PROCESSING COMPLETED FOR L2
L3            10 DUPLICATE REMOVE L2 (0 DUPLICATES REMOVED)

=> d ibib abs 1-10


L3   ANSWER 1 OF 10  CAPLUS  COPYRIGHT 2000 ACS
ACCESSION NUMBER:         1999:325800  CAPLUS
DOCUMENT NUMBER:          130:357131
TITLE:                    Medicine containing thrombocytes for promoting
                          cicatrization
INVENTOR(S):              Braun, Friedrich; Spaengler, Hans-Peter; Eibl, Johann
PATENT ASSIGNEE(S):       Bio-Products & Bio-Engineering Aktiengesellschaft,
                          Austria
SOURCE:                   PCT Int. Appl., 23 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 German
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.        KIND  DATE           APPLICATION NO.  DATE
     ---------------   ----  --------       ---------------  --------
     WO 9924044         A1   19990520       WO 1998-AT278    19981112
         W:  AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
             DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE,
             KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW,
             MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR,
             TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ,
TM
         RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
             FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
```

CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 9911354	A1	19990531	AU 1999-11354	19981112
EP 966293	A1	19991229	EP 1998-954056	19981112

R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE, IE

PRIORITY APPLN. INFO.:	AT 1997-1916	19971112
	WO 1998-AT278	19981112

AB A pharmaceutical compn. for local administration to promote cicatrization contains thrombocytes or **thrombocyte** fragments which contain growth factors capable of being discharged. The thrombocytes are freeze-dried or frozen and are subjected to a process for depleting and/or inactivating viruses. Thus, a human platelet conc. was anticoagulated with 3% Na citrate, centrifuged, washed, dild. to 6 .times. 105/.mu.L, subjected to photodynamic virus inactivation with UV radiation (3.5-4.8 mW/cm2) under CO2/N2 (5:95) at 2-6 psi in the presence of 8-methoxypsoralen, and deep-frozen or lyophilized.

REFERENCE COUNT: 4

REFERENCE(S):
(1) Arlozorov ZG; SU 353724 A
(2) Cryopharm Corp; WO 9117655 A 1991
(3) Theratechnologies Inc; WO 9734614 A 1997
(4) Valeri, C; Blood 1974, V43(1), P131 CAPLUS

L3 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2000 ACS

ACCESSION NUMBER: 1999:113926 CAPLUS

DOCUMENT NUMBER: 130:165139

TITLE: Method and device for the preparation of autologous **thrombocyte** growth factors

INVENTOR(S): Flesch, Ingo; Brand, Volker

PATENT ASSIGNEE(S): Germany

SOURCE: Ger. Offen., 6 pp.
CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19733899	A1	19990211	DE 1997-19733899	19970805
WO 9907742	A1	19990218	WO 1998-EP4520	19980720

W: AL, AM, AU, BB, BG, BR, CA, CN, CZ, EE, HU, IS, JP, KR, LT, LV, MK, MX, NZ, PL, RO, SD, SG, SI, SK, TR, US, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 9889779	A1	19990301	AU 1998-89779	19980720
EP 1001988	A1	20000524	EP 1998-941379	19980720

R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE

PRIORITY APPLN. INFO.:	DE 1997-19733899	19970805
	WO 1998-EP4520	19980720

AB The invention concerns a method and device for the prepn. of autologous **thrombocyte** growth factors from **thrombocyte** conc. by degranulating the thrombocytes with a mixt. of calcium and thrombin and liberating the granula that contain the growth factors; the samples are freeze-shocked thereafter. The assembly can be part of a bed-side blood sepn. device; the product is applied for promoting **wound healing**.

L3 ANSWER 3 OF 10 MEDLINE

ACCESSION NUMBER: 1999195056 MEDLINE

DOCUMENT NUMBER: 99195056

TITLE: [Proliferation and **wound healing** of retinal pigment epithelium cells in vitro. Effect of human **thrombocyte** concentrate, serum and PDGF].

Proliferation und Wundheilung von RPE-Zellen in vitro. Einfluss von humanem Thrombozytenkonzentrat, Serum und PDGF.
AUTHOR: Velhagen K H; Druegg A; Rieck P
CORPORATE SOURCE: Augenklinik der Charite, Humboldt-Universitat Berlin.
SOURCE: OPHTHALMOLOGE, (1999 Feb) 96 (2) 77-81.
Journal code: BGV. ISSN: 0941-293X.
PUB. COUNTRY: GERMANY: Germany, Federal Republic of
Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: German
ENTRY MONTH: 199908
ENTRY WEEK: 19990803
AB PURPOSE: Biological agents like human serum or autologous platelets have recently been employed as adjuvants for macular hole surgery. However, the role of these agents on the retinal cellular level remains unclear. In the present study, we investigated the effect of human platelets, serum and PDGF on RPE migration and proliferation in cell culture. METHODS: Human RPE were cultured in DMEM + 2% FCS and experiments performed at passages 2-4. Human platelet concentrate (PC) and serum (HS) were isolated from blood of patients previewed for macular hole surgery; human PDGF-BB was from Pepro Tech. PC and HS at protein concentrations ranging from 50-1000 micrograms/ml and PDGF at 1 and 10 ng/ml were added to 5000 cells/well in the proliferation assay and to a confluent RPE monolayer on which a central mechanical "wound" (5 mm diameter) was made. Incubation times ranged from 1 h to 5 days. Cell numbers at D 5 were indirectly determined by protein measurements. In the wound model, the cells inside the wound area were counted and results compared to the control cultures that received no supplements. RESULTS: Cell proliferation was significantly stimulated over controls by all concentrations of PC, HS and PDGF with any incubation time. Compared to PC and PDGF, HS revealed less proliferation after 1-6 h of incubation; there was no significant difference from PC with other incubation times. In the wound model, both PC and PDGF significantly increased the number of cells migrating into the denuded area after 1 h incubation with the culture medium; longer incubation times had no further effect compared to controls. CONCLUSION: The present study is the first to demonstrate that human platelet concentrate induces proliferation and migration of RPE cells in vitro. However, PDGF, a growth factor which is abundantly present in platelets, was found to be at least equally effective. We assume that the majority of the mitogenic effect of platelet concentrate is due to PDGF.

L3 ANSWER 4 OF 10 MEDLINE
ACCESSION NUMBER: 1998254082 MEDLINE
DOCUMENT NUMBER: 98254082
TITLE: Beneficial effect of Iloprost on impaired colonic anastomotic healing induced by intraperitoneal 5-fluorouracil infusion.
AUTHOR: Bostanoglu S; Dincer S; Keskin A; Bostanoglu A; Dursun A; Serim C
CORPORATE SOURCE: 6th Department of Surgery, Ankara Numune Hospital, Turkey.
SOURCE: DISEASES OF THE COLON AND RECTUM, (1998 May) 41 (5) 642-8.
Journal code: EAB. ISSN: 0012-3706.
PUB. COUNTRY: United States
Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals; Cancer Journals
ENTRY MONTH: 199808
ENTRY WEEK: 19980801
AB PURPOSE: 5-Fluorouracil is the most effective chemotherapeutic agent in

the management of patients with systemic colorectal cancer. Studies in recent years discussed the gradually increasing benefits of 5-fluorouracil within adjuvant chemotherapy protocols after complete surgical resections. However, many studies also have demonstrated that 5-fluorouracil impairs **wound-healing** on colonic anastomoses. METHODS: In our experimental study, we examined the influence of intraperitoneal 5-fluorouracil on healing of colonic anastomoses and, also, attempted to discover whether Iloprost (PGI2 analog, a potent vasodilator with confirmed cytoprotectivity and inhibitor of **thrombocyte** aggregation) counteracts impaired **wound-healing** induced by 5-fluorouracil. A total of 80 Wistar-Albino male rats were separated into four groups. From the day of the operation, Group A received intraperitoneal saline solution, Group B received 20 mg/kg 5-fluorouracil intraperitoneally, Group C received 20 mg/kg 5-fluorouracil plus 2 microg/kg Iloprost intraperitoneally, and Group D received 2 microg/kg Iloprost intraperitoneally. Each group was divided into two subgroups, and both subgroups were killed on the third and seventh postoperative days, respectively. The subjects were measured for anastomose bursting pressures and tissue hydroxyproline levels, and **wound-healing** was evaluated histopathologically. Statistical evaluations among each group were made with Student's t-test and Pearson's chi-squared tests. RESULTS: Iloprost had an accelerating effect on normal colonic anastomose **wound-healing** histopathologically, had no significant difference on bursting pressures and hydroxyproline levels, and significantly improved the impaired healing effect of 5-fluorouracil. CONCLUSIONS: Our study showed a positive effect of Iloprost on the healing of colon anastomosis and, more importantly, if **wound-healing** is impaired by a chemotherapeutic agent, Iloprost counteracts and reverses the effect. [Key words: 5-Fluorouracil; Healing of colon anastomoses; Iloprost

L3 ANSWER 5 OF 10 MEDLINE
ACCESSION NUMBER: 1998148737 MEDLINE
DOCUMENT NUMBER: 98148737
TITLE: [Autologous **thrombocyte** administration in treatment of idiopathic macular foramen]. Autologe Thrombozytenapplikation bei der Behandlung des idiopathischen Makulaforamens.
AUTHOR: Faude F; Edel E; Dannhauer M; Petzel C; Meier P; Wiedemann P
CORPORATE SOURCE: Universitats-Augenklinik Leipzig.
SOURCE: OPHTHALMOLOGE, (1997 Dec) 94 (12) 877-81. Journal code: BGV. ISSN: 0941-293X.
PUB. COUNTRY: GERMANY: Germany, Federal Republic of
Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: German
ENTRY MONTH: 199806
ENTRY WEEK: 19980604
AB BACKGROUND: Recent studies have shown the usefulness of pars plana vitrectomy with the use of growth factors in the treatment of macular holes. Autologous platelet concentrates contain many growth factors to stimulate glial **wound healing**. PATIENTS: Nineteen patients with idiopathic macular hole underwent vitrectomy, membrane peeling, air injection and installation of autologous platelet concentrate (0.1 ml). The platelet concentrate contained a mean of 1.8 x 10(9) platelets/ml. RESULTS: The anatomic success rate in stage 2 macular hole was 100%, in stage 3, 82% and in stage 4, 50%. Visual acuity improved in all patients with stage 2 (two lines) and in 73% of stage 3 at least (one line). CONCLUSION: Platelets are effective in the treatment of macular holes due to the high amount of different growth factors (PDGF, EGF, bFGF,

IGF-1) which have a high affinity binding to Muller cells helping to seal the hole by photoreceptor adaption.

L3 ANSWER 6 OF 10 MEDLINE
ACCESSION NUMBER: 97441348 MEDLINE
DOCUMENT NUMBER: 97441348
TITLE: [Local therapy of chronic arterial leg ulcers with **thrombocyte** growth factor].
Die lokale Therapie chronisch-arterieller Ulcera cruris mit
thrombocytaren Wachstumsfaktoren.
AUTHOR: Jessberger S; Debus E S; Schmidt K; Reith H B; Thiede A
CORPORATE SOURCE: Chirurgischen Klinik und Poliklinik, Universitat Wurzburg.
SOURCE: KRANKENPFLEGE JOURNAL, (1997 Jul-Aug) 35 (7-8) 293-6.
Journal code: KYN. ISSN: 0174-108X.
PUB. COUNTRY: GERMANY: Germany, Federal Republic of
Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: German
FILE SEGMENT: Nursing Journals; Nursing
ENTRY MONTH: 199803
ENTRY WEEK: 19980302

L3 ANSWER 7 OF 10 MEDLINE
ACCESSION NUMBER: 94327114 MEDLINE
DOCUMENT NUMBER: 94327114
TITLE: [Stimulation of **wound healing** with **thrombocyte** growth factors in treatment of chronic unhealed wounds].
Stimulation der Wundheilung mit thrombozytaren Wachstumsfaktoren bei der Behandlung chronisch nicht-heilender Wunden.
AUTHOR: Flesch I; Koveker G; Tolksdorf-Kremmer A; Coerper S; Becker
H D
CORPORATE SOURCE: Abteilung fur Allgemeine Chirurgie und Poliklinik, Eberhard-Karls-Universitat, Klinikum Schnarrenberg in Tubingen..
SOURCE: HANDCHIRURGIE, MIKROCHIRURGIE, PLASTISCHE CHIRURGIE, (1994 May) 26 (3) 160-4.
Journal code: FY6. ISSN: 0722-1819.
PUB. COUNTRY: GERMANY: Germany, Federal Republic of
Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: German
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199411
AB The management of chronic wounds remains a challenge for various medical and surgical specialties. General strategies include local wound care, surgery, skin grafting, debridement, and vascular reconstruction. However,
many wounds remain resistant to conventional therapies. Because platelet factors are important in the normal mechanism of **wound healing**, we report on the topical application of platelet-derived growth factor. Our initial results suggest that the topical application may stimulate and promote healing of chronic wounds.

L3 ANSWER 8 OF 10 MEDLINE
ACCESSION NUMBER: 91007833 MEDLINE
DOCUMENT NUMBER: 91007833
TITLE: [**Thrombocyte** growth factor].
Thrombozyten-Wachstumsfaktor.
AUTHOR: Buck C; Montenarh M
CORPORATE SOURCE: Medizinische Universitatsklinik und Poliklinik, Abteilung Innere Medizin III-Hamatologie/Onkologie, Ulm..
SOURCE: IMMUNITAT UND INFEKTION, (1990 Aug) 18 (4) 132-5. Ref: 50

Journal code: GH1. ISSN: 0340-1162.
PUB. COUNTRY: GERMANY: Germany, Federal Republic of
Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LANGUAGE: German
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199101
AB PDGF is one of the principal mitogens for cultured cells of mesenchymal origin. Apart from aggregated platelets PDGF can be secreted by a number of cells. There is a striking homology between the amino-acid sequence of PDGF and that of a transforming protein of simian-sarcoma virus. PDGF is an important chemotactic protein for cells implicated in **wound healing**. Furthermore, recent publications suggest a possible role in the pathogenesis of several diseases. This article summarizes studies and recent findings on the structure, biology, and functional role of PDGF.

L3 ANSWER 9 OF 10 MEDLINE
ACCESSION NUMBER: 82268321 MEDLINE
DOCUMENT NUMBER: 82268321
TITLE: The use of the fibrin adhesion system for local hemostasis in oral surgery.
AUTHOR: Wepner F; Fries R; Platz H
SOURCE: JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, (1982 Sep) 40 (9) 555-8.
Journal code: JIC. ISSN: 0278-2391.
PUB. COUNTRY: United States
Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals; Dental Journals
ENTRY MONTH: 198212
AB In 144 patients with bleeding disorders and in 11 patients with normal coagulation, 517 wound sealings were performed using the fibrin adhesion system (FAS) with the primary object of local hemostasis. Excellent results were obtained in patients with bleeding disorders caused by impaired **thrombocyte** function or anticoagulant therapy. Replacement therapy or the withdrawal of anticoagulant medication was thereby avoided. Ultimate hemostasis in patients with hemophilia was achieved by fibrin sealing in combination with low-dose replacement therapy with clotting factor concentrates. Though the risk of hepatitis transmission cannot be completely ruled out, the advantages, such as excellent tissue tolerance, complete resorption, and a wide spectrum of practical uses, speak in favor of the use of this physiologic tissue adhesive.

L3 ANSWER 10 OF 10 MEDLINE
ACCESSION NUMBER: 81066733 MEDLINE
DOCUMENT NUMBER: 81066733
TITLE: Lupus anticoagulant after measles.
AUTHOR: Muntean W; Petek W
SOURCE: EUROPEAN JOURNAL OF PEDIATRICS, (1980 Aug) 134 (2) 135-8.
Journal code: END. ISSN: 0340-6199.
PUB. COUNTRY: GERMANY, WEST: Germany, Federal Republic of
Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 198104
AB A 2 2/12 years old boy developed a "lupus anticoagulant" after measles. Fibrinogen concentration and activity of factors II, V, VII, VIII, IX, X, XI and XII were normal, but partial thromboplastin time and thromboplastin time were prolonged. Thrombin time was within the normal range. Mixing

normal plasma with the patient's plasma immediately prolonged the partial thromboplastin time, and incubation of the sample did not increase the inhibition. The immunglobulin fraction prepared from the patient's plasma on DEAE-sephacel also prolonged the partial thromboplastin time in cross mixing experiments. The **thrombocyte** count and **thrombocyte** functions were normal. In spite of the pathological partial thromboplastin and thromboplastin times, surgery was performed without excessive bleeding during the operation and without delayed **wound healing**.

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	17.04	17.34

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.11	-1.11

STN INTERNATIONAL LOGOFF AT 19:18:00 ON 09 AUG 2000

=> d L15 ibib ti so abs 1-5

L15 ANSWER 1 OF 9 EUROPATFULL COPYRIGHT 2000 WILA

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

ACCESSION NUMBER: 765157 EUROPATFULL EW 199912 FS PS
TITLE: PELLETS.
PELLETS.
PILULES.
INVENTOR(S): NORLING, Tomas, Mollevanget 36, DK-2800 Lyngby, DK;
JORGENSEN, Lone Norgaard, Birkebakken 61, DK-3460 Birkerod, DK;
HANSEN, Jens, Petuniavej 3, DK-3450 Allerod, DK
PATENT ASSIGNEE(S): DUMEX-ALPHARMA A/S, Dalslandsgade 11, 2300 Copenhagen S, DK
PATENT ASSIGNEE NO: 223953
AGENT: Plougmann, Vingtoft & Partners A/S, Sankt Annae Plads 11, P.O. Box 3007, 1021 Copenhagen K, DK
AGENT NUMBER: 101171
OTHER SOURCE: EPB1999018 EP 0765157 B1 990324
SOURCE: Wila-EPS-1999-H12-T1
DOCUMENT TYPE: Patent
LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch
DESIGNATED STATES: R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE
PATENT INFO.PUB.TYPE: EPB1 EUROPAEISCHE PATENTSCHRIFT (Internationale Anmeldung)
PATENT INFORMATION:

PATENT NO	KIND	DATE
EP 765157	B1	19990324
'OFFENLEGUNGS' DATE:		19970402
APPLICATION INFO.:	EP 1995-922430	19950614
PRIORITY APPLN. INFO.:	DK 1994-695	19940615
RELATED DOC. INFO.:	WO 95-DK240	950614 INTAKZ
	WO 9534291	951221 INTPNR
REFERENCE PAT. INFO.:	EP 378137 A	EP 452862 A
	WO 87-02240 A	FR 2292747 A
	US 4164572 A	

REF. NON-PATENT-LIT.: DATABASE WPI Week 9247, Derwent Publications Ltd., London, GB; AN 92-385400 &
JP-A-4283520 (ASAHI CHEM IND CO LTD) 8 October 1992
DATABASE WPI Week 7825, Derwent Publications Ltd., London, GB; AN 78-44930A &
JP-A-53052626 (KUMIAI CHEM IND KK) 13 May 1978
TIEN PELLETS.
SO Wila-EPS-1999-H12-T1

L15 ANSWER 2 OF 9 EUROPATFULL COPYRIGHT 2000 WILA

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

ACCESSION NUMBER: 752855 EUROPATFULL EW 199923 FS PS
TITLE: USE OF FATTY ACID ESTERS AS BIOADHESIVE SUBSTANCES.
VERWENDUNG VON FETTSAeUREESTER ALS BIOKLEBSTOFFE.
UTILISATION D'ESTERS D'ACIDES GRAS COMME SUBSTANCES BIOADHERENTES.
INVENTOR(S): HANSEN, Jens, Petuniavej 3, DK-3450 Allerod, DK;

SYLVEST NIELSEN, Lise, Drejogade 17, 3.tv, DK-2100 Copenhagen, DK;
NORLING, Tomas, Mollevaenget 36, DK-2800 Lyngby, DK

PATENT ASSIGNEE(S): GS DEVELOPMENT AB, Jaegershillgatan 15, S-213 75 Malmoe, SE

PATENT ASSIGNEE NO: 1747800

AGENT: Plougmann, Vingtoft & Partners A/S, Sankt Annae Plads 11, P.O. Box 3007, 1021 Copenhagen K, DK

AGENT NUMBER: 101171

OTHER SOURCE: EPB1999034 EP 0752855 B1 990609

SOURCE: Wila-EPS-1999-H23-T1

DOCUMENT TYPE: Patent

LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch

DESIGNATED STATES: R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE

PATENT INFO.PUB.TYPE: EPB1 EUROPAEISCHE PATENTSCHRIFT (Internationale Anmeldung)

PATENT INFORMATION:

PATENT NO	KIND	DATE
EP 752855	B1	19990609
'OFFENLEGUNGS' DATE:		19970115
APPLICATION INFO.: EP 1995-915817		19950329
PRIORITY APPLN. INFO.: DK 1994-370		19940330
RELATED DOC. INFO.: WO 95-DK143		950329 INTAKZ
WO 9526715		951012 INTPNR

REF. NON-PATENT-LIT.: DATABASE WPI Week 8748 Derwent Publications Ltd., London, GB; AN 87-337219 & JP,A,62 240 614 (SEKISUI), 21 October 1987 DATABASE WPI Week 8824 Derwent Publications Ltd., London, GB; AN 88-164050 & JP,A,63 101 316 (NICHIBAN), 6 May 1988

TIEN USE OF FATTY ACID ESTERS AS BIOADHESIVE SUBSTANCES.

SO Wila-EPS-1999-H23-T1

L15 ANSWER 3 OF 9 USPATFULL

ACCESSION NUMBER: 1999:117030 USPATFULL

TITLE: Pharmaceutical multiple unit particulate formulation in the form of coated cores

INVENTOR(S): Norling, Tomas, Lyngby, Denmark
Jensen, Lone Norgaard, Soborg, Denmark
Hansen, Jens, Allerod, Denmark

PATENT ASSIGNEE(S): Dumex-Alpharma A/S, Copenhagen, Denmark (non-U.S. corporation)

NUMBER	DATE
PATENT INFORMATION: US 5958458	19990928
APPLICATION INFO.: US 1995-509107	19950801 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1994-268037, filed on 29 Jun 1994

NUMBER	DATE
PRIORITY INFORMATION: DK 1994-695	19940615

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Webman, Edward J.

LEGAL REPRESENTATIVE: Watov & Kipnes, P.C.

NUMBER OF CLAIMS: 20

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 8 Drawing Figure(s); 8 Drawing Page(s)

LINE COUNT: 2292

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

TI Pharmaceutical multiple unit particulate formulation in the form of coated cores

AB A pharmaceutical multiple unit particulate formulation in the form of coated cores which includes a pharmaceutically acceptable carrier

selected from calcium carbonate, calcium silicate, calcium magnesium silicate, calcium phosphate, kaolin, sodium hydrogen carbonate, sodium **sulfate**, barium carbonate, barium **sulfate**, magnesium **sulfate**, magnesium carbonate, and activated carbon, and an active substance in a layer on the outer surface of the cores.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 4 OF 9 USPATFULL

ACCESSION NUMBER:	1999:113787 USPATFULL
TITLE:	Use of fatty acid esters as bioadhesive substances
INVENTOR(S):	Hansen, Jens, Allerod, Denmark Nielsen, Lise Sylvest, Copenhagen .O slashed., Denmark Norling, Tomas, Lyngby, Denmark
PATENT ASSIGNEE(S):	GS Development AB, Malmo, Sweden (non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5955502	19990921
APPLICATION INFO.:	US 1997-829496	19970327 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1997-462222, filed on 5 Jun 1997	
PRIORITY INFORMATION:	DK 1994-37	19940330

DOCUMENT TYPE:	Utility
PRIMARY EXAMINER:	MacMillan, Keith D.
LEGAL REPRESENTATIVE:	Watov & Kipnes, P.C.
NUMBER OF CLAIMS:	22
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	7 Drawing Figure(s); 6 Drawing Page(s)
LINE COUNT:	2331

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

TI Use of fatty acid esters as bioadhesive substances

AB Use of fatty acid esters as bioadhesive substances. The fatty acid esters have molecular weights below about 1000 dalton and the fatty acid component of the fatty acid ester is a saturated or unsaturated fatty acid having a total number of carbon atoms of from C.sub.8 to C.sub.22. Particularly suitable fatty acid esters for use according to the invention are fatty acid esters which are selected from the group consisting of fatty acid esters of polyhydric alcohols, fatty acid esters of hydroxycarboxylic acids, fatty acid esters of monosaccharides, fatty acid esters of glycerylphosphate **derivatives**, fatty acid esters of glycerylsulfate **derivative**, and mixtures thereof. Excellent bioadhesive properties have been observed for fatty acid esters are glyceryl monooleate, glyceryl monolinoleate or glyceryl monolinolenate.

Methods are described for administering an active or protective substance to undamaged or damaged skin or mucosa of an animal such as a human by combining the active or protective substance with a bioadhesive fatty acid ester. The mucosa may be the oral, aural, nasal, lung, gastrointestinal, vaginal, or rectal mucosa. The administration may also be to body cavities such as the oral cavity, e.g. via buccal administration.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 5 OF 9 USPATFULL

ACCESSION NUMBER:	1998:147065 USPATFULL
TITLE:	Loading of biologically active solutes into polymer gels
INVENTOR(S):	Roos, Eric J., 1 Barbara Jean St., Grafton, MA, United States 01519 Schiller, Matthew E., 23C Sagamore Way, Waltham, MA,

United States 02154

	NUMBER	DATE
PATENT INFORMATION:	US 5840338	19981124
APPLICATION INFO.:	US 1995-556130	19951106 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1994-276462, filed on 18 Jul 1994, now patented, Pat. No. US 5603955 And a continuation-in-part of Ser. No. US 1994-276193, filed on 18 Jul 1994

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Webman, Edward J.
LEGAL REPRESENTATIVE: Choate, Hall& Stewart
NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 25 Drawing Figure(s); 12 Drawing Page(s)
LINE COUNT: 4589
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

TI Loading of biologically active solutes into polymer gels

AB Polymer gel networks loaded with biologically active solutes in a manner that solute activity is maintained and protected from thermal and/or chemical degradation while in the gel network are provided. The invention also provides for effects of modulating parameters for loading safe responsive gel networks using loading solutions containing phase separating polymers.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d L15 ibib ti so abs 6-10

'SO' IS NOT A VALID FORMAT
In a multifile environment, a format can only be used if it is valid in at least one of the files. Refer to file specific help messages or the STNGUIDE file for information on formats available in individual files.
REENTER DISPLAY FORMAT FOR ALL FILES (FILEDEFAULT):filedefault

L15 ANSWER 6 OF 9 USPATFULL
AN 1998:82361 USPATFULL
TI Methods and articles of manufacture for nicotine cessation and monitoring nicotine use
IN Eswara, Amruta R., Beverly, MA, United States
Muni, Neal, N. Reading, MA, United States
Schneider, F. Howard, Yarmouth, MA, United States
Mione, Peter J., Abington, MA, United States
PA DynaGen, Inc., Cambridge, MA, United States (U.S. corporation)
PI US 5780051 19980714
AI US 1997-779281 `19970122 (8)
RLI Continuation-in-part of Ser. No. US 1995-487853, filed on 7 Jun 1995, now abandoned And Ser. No. US 1992-881740, filed on 7 May 1992 which is a division of Ser. No. US 1993-135847, filed on 13 Oct 1993, now patented, Pat. No. US 5403595 which is a division of Ser. No. US 1995-415859, filed on 3 Apr 1995, now patented, Pat. No. US 5536503 which is a division of Ser. No. US 1993-145203, filed on 28 Oct 1993, now patented, Pat. No. US 5414005 which is a division of Ser. No. US 1992-862051, filed on 2 Apr 1992, now abandoned which is a division of Ser. No. US 1993-137687, filed on 15 Oct 1993, now abandoned which is a division of Ser. No. US 1994-279619, filed on 25 Jul 1994
DT Utility
LN.CNT 1863
INCL INCLM: 424/449.000
INCLS: 424/423.000; 424/425.000; 424/426.000; 424/451.000; 424/501.000; 424/502.000; 514/810.000; 514/811.000; 514/812.000; 514/813.000; 514/953.000; 514/955.000; 514/963.000; 514/965.000

NCL NCLM: 424/449.000
NCLS: 424/423.000; 424/425.000; 424/426.000; 424/451.000; 424/501.000; 424/502.000; 514/810.000; 514/811.000; 514/812.000; 514/813.000; 514/953.000; 514/955.000; 514/963.000; 514/965.000
IC [6]
ICM: A61K009-70
ICS: A61K009-48; A61K009-50; A61F002-02
EXF 424/423; 424/425; 424/426; 424/449; 424/451; 424/501; 424/502; 514/810; 514/811; 514/812; 514/813; 514/953; 514/955; 514/963; 514/965
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 7 OF 9 USPATFULL
AN 97:91191 USPATFULL
TI Enhanced loading of solutes into polymer gels and methods of use
IN Gehrke, Steven Henry, Cincinnati, OH, United States
Lupton, E. C., Boston, MA, United States
Schiller, Matthew E., Waltham, MA, United States
Uhden, Lorelle, Cincinnati, OH, United States
Vaid, Nitin, Kanpur, India
PA University of Cincinnati, Cincinnati, OH, United States (U.S. corporation)
PI US 5674521 19971007
AI US 1995-425275 19950420 (8)
RLI Division of Ser. No. US 1994-276462, filed on 18 Jul 1994, now patented, Pat. No. US 5603955
DT Utility
LN.CNT 1966
INCL INCLM: 424/423.000
INCLS: 514/772.300; 514/781.000
NCL NCLM: 424/423.000
NCLS: 514/772.300; 514/781.000
IC [6]
ICM: A61F002-02
ICS: A61K047-30
EXF 424/423; 514/772.3; 514/781
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 8 OF 9 USPATFULL
AN 97:14434 USPATFULL
TI Enhanced loading of solutes into polymer gels
IN Gehrke, Stevin H., Cincinnati, OH, United States
Lupton, E. C., Boston, MA, United States
Schiller, Matthew E., Waltham, MA, United States
Uhden, Lorelle, Cincinnati, OH, United States
Vaid, Nitin, Kanpur, India
PA University of Cincinnati, Cincinnati, OH, United States (U.S. corporation)
PI US 5603955 19970218
AI US 1994-276462 19940718 (8)
DT Utility
LN.CNT 1934
INCL INCLM: 424/484.000
INCLS: 424/486.000; 424/488.000; 424/487.000; 514/944.000; 252/315.200; 252/315.400; 252/315.300
NCL NCLM: 424/484.000
NCLS: 424/486.000; 424/487.000; 424/488.000; 514/944.000; 516/102.000; 516/104.000; 516/105.000; 516/106.000; 516/107.000
IC [6]
ICM: A61K009-10
ICS: A61K047-32; A61K047-34; A61K047-36
EXF 424/484; 424/486
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 9 OF 9 USPATFULL
AN 96:24940 USPATFULL
TI HIV protease inhibitor compounds

IN Dorsey, Bruce D., Harleysville, PA, United States
Huff, Joel R., Gwynedd Valley, PA, United States
Britcher, Susan F., Norristown, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 5502053 19960326
AI US 1994-294772 19940823 (8)
RLI Continuation of Ser. No. US 1992-944568, filed on 14 Sep 1992, now abandoned
DT Utility
LN.CNT 1851
INCL INCLM: 514/239.200
INCLS: 514/233.400; 514/432.000; 514/621.000; 544/162.000; 544/145.000; 549/023.000; 564/169.000; 564/164.000; 564/163.000; 564/158.000; 564/155.000
NCL NCLM: 514/239.200
NCLS: 514/233.500; 514/432.000; 514/621.000; 544/145.000; 544/162.000; 549/023.000; 564/155.000; 564/158.000; 564/163.000; 564/164.000; 564/169.000
IC [6]
ICM: A61K031-395
ICS: C07D265-28
EXF 564/169; 564/155; 564/158; 564/163; 564/164; 514/621; 514/239.2; 514/233.5; 514/432; 544/162; 544/145; 549/23
CAS INDEXING IS AVAILABLE FOR THIS PATENT.